Dry Eye Disease

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.

Wow! That was quick. Another year has come and gone, the pages of the calendar flying by like one of those old cartoon flip chart things.

Harrow announced three partnerships to support the upcoming launch of Vevye, indicated for treating the signs and symptoms of dry eye disease.

Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.

There are certain things that are a must for me in the preop cataract setting from a diagnostic standpoint.

The top Healio cornea-related articles in 2023 included the FDA approval of Vevye for dry eye disease and the efficacy of azithromycin in the treatment of meibomian gland dysfunction.

The office-based thermal eyelid treatment TearCare significantly improved tear breakup time and measures of meibomian gland secretion compared with Restasis in patients with dry eye disease, according to 6-month trial data.

There has certainly been a whole bunch of new stuff around the dry eye disease ranch, hasn’t there?

Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.

Oculis has announced the first patient first visit in its phase 2b RELIEF trial evaluating licaminlimab, the company’s novel anti-tumor necrosis factor-alpha biologic eye drop, for treatment of moderate to severe dry eye disease.